Josef Vejvoda - Acerus Pharmaceuticals Director
| ASPCFDelisted Stock | USD 0.22 0.00 0.00% |
Director
Mr. Josef Vejvoda is Director of Acerus Pharmaceuticals Corporationrationration. Mr. Vejvoda has extensive experience in capital markets and corporate governance. He is currently a portfolio manager at K2 Associates Investment Management Inc., a multistrategy investment firm, and president of Jove Capital Inc., a boutique financial services firm. Mr. Vejvoda serves on the board of directors of Absolute Software Corporationration, where he is also a member of the audit committee and governance and nominating committee, and ShoreTel Inc., where he is also a member of the compensation committee and corporate governance and nominating committee. His previous experience includes managing director and head of investment banking at MGI Securities Inc., a Canadian investment dealer, and senior roles at a number of Canada largest financial institutions, including Merrill Lynch Canada, Bank of Montreal, National Bank Financial and TD Securities. He is a bachelor of computer science graduate from Queen University and is a registered portfolio manager with the Ontario Securities Commission. Mr. Vejvoda has also earned the chartered investment manager designation from the Canadian Securities Institute and the ICDD designation from Institute of Corporationrationrate Directors. since 2015.
| Age | 50 |
| Tenure | 9 years |
| Phone | 416 679 0771 |
| Web | https://www.aceruspharma.com |
Acerus Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.541) % which means that it has lost $0.541 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (22.4197) %, meaning that it generated substantial loss on money invested by shareholders. Acerus Pharmaceuticals' management efficiency ratios could be used to measure how well Acerus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 21.14 M in total debt with debt to equity ratio (D/E) of 2.61, implying the company greatly relies on financing operations through barrowing. Acerus Pharmaceuticals has a current ratio of 0.36, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Acerus Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Acerus Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Acerus Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Acerus to invest in growth at high rates of return. When we think about Acerus Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Hamish Dodds | Dave Busters Entertainment | 60 | |
| Jennifer Storms | Dave Busters Entertainment | 45 | |
| Peter Brandow | National CineMedia | 55 | |
| Mark Ain | KVH Industries | 74 | |
| Dan Dorenkamp | National CineMedia | N/A | |
| Stanley Honey | KVH Industries | 62 | |
| Mark Segall | National CineMedia | 55 | |
| Kevin Sheehan | Dave Busters Entertainment | 64 | |
| Paula Madison | National CineMedia | 63 | |
| Andrew Glaze | National CineMedia | 39 | |
| Socrates Verses | Comstock Holding Companies | 56 | |
| Charles Trimble | KVH Industries | 76 | |
| Stephen Lanning | National CineMedia | 62 | |
| Robert Pincus | Comstock Holding Companies | 69 | |
| Renana Teperberg | National CineMedia | 40 | |
| Robert Heyningen | KVH Industries | 58 | |
| Tyler Wolfram | Dave Busters Entertainment | 47 | |
| Victor Crawford | Dave Busters Entertainment | 55 | |
| Clayton Perfall | Comstock Holding Companies | 57 | |
| Kurt Hall | National CineMedia | 58 | |
| Gregory Benson | Comstock Holding Companies | 58 | |
Management Performance
| Return On Equity | -22.42 | |||
| Return On Asset | -0.54 |
Acerus Pharmaceuticals Leadership Team
Elected by the shareholders, the Acerus Pharmaceuticals' board of directors comprises two types of representatives: Acerus Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Acerus. The board's role is to monitor Acerus Pharmaceuticals' management team and ensure that shareholders' interests are well served. Acerus Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Acerus Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gavin Damstra, VP Commercial | ||
| Ian Ihnatowycz, Independent Chairman of the Board | ||
| Robert Motz, CFO | ||
| Matthew Hawkins, Vice President - Legal Affairs, Corporate Secretary | ||
| Josef Vejvoda, Director | ||
| Edward Gudaitis, President CEO, Director | ||
| Borys Chabursky, Director | ||
| Mark Lievonen, Director | ||
| Naveed Manzoor, Interim Officer | ||
| Stephen Gregory, Lead Independent Director | ||
| Kevin Hickey, VP Commercial | ||
| Tricia Symmes, COO | ||
| Norma Beauchamp, Director | ||
| FACE MD, Chief Officer | ||
| Chris Witty, Investor Relations | ||
| Jeffrey Sherman, Independent Director | ||
| Rolf Reininghaus, Executive Director, Director | ||
| Hubert Czerwinski, Pres SRL | ||
| Philippe Savard, Gen VP | ||
| Nathan Bryson, Vice President - Scientific Affairs |
Acerus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Acerus Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -22.42 | |||
| Return On Asset | -0.54 | |||
| Operating Margin | (8.41) % | |||
| Current Valuation | 49.66 M | |||
| Shares Outstanding | 7.71 M | |||
| Shares Owned By Insiders | 91.41 % | |||
| Price To Book | 20.08 X | |||
| Price To Sales | 2.16 X | |||
| Revenue | (4.13 M) | |||
| Gross Profit | 1 M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Acerus Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Acerus Pharmaceuticals' short interest history, or implied volatility extrapolated from Acerus Pharmaceuticals options trading.
Pair Trading with Acerus Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acerus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acerus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Acerus OTC Stock
| 0.84 | TEVA | Teva Pharmaceutical | PairCorr |
| 0.48 | TPDDF | Talon Energy | PairCorr |
| 0.47 | MKKGY | Merck KGaA ADR | PairCorr |
| 0.47 | MKGAF | MERCK Kommanditgesells | PairCorr |
| 0.45 | LRDG | Lord Global Corp | PairCorr |
The ability to find closely correlated positions to Acerus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acerus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acerus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acerus Pharmaceuticals to buy it.
The correlation of Acerus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acerus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acerus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acerus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Acerus Pharmaceuticals information on this page should be used as a complementary analysis to other Acerus Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Other Consideration for investing in Acerus OTC Stock
If you are still planning to invest in Acerus Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acerus Pharmaceuticals' history and understand the potential risks before investing.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |